JPMorgan Chase & Co. Reduces Position in Zimmer Biomet Holdings, Inc. $ZBH

JPMorgan Chase & Co. decreased its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 4.3% in the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 889,356 shares of the medical equipment provider’s stock after selling 39,546 shares during the quarter. JPMorgan Chase & Co. owned 0.45% of Zimmer Biomet worth $87,602,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of ZBH. Key Financial Inc grew its stake in shares of Zimmer Biomet by 164.6% in the third quarter. Key Financial Inc now owns 262 shares of the medical equipment provider’s stock worth $26,000 after acquiring an additional 163 shares during the period. Cullen Frost Bankers Inc. lifted its position in Zimmer Biomet by 66.7% during the third quarter. Cullen Frost Bankers Inc. now owns 290 shares of the medical equipment provider’s stock valued at $29,000 after purchasing an additional 116 shares during the period. Cary Street Partners Investment Advisory LLC boosted its holdings in Zimmer Biomet by 83.7% in the second quarter. Cary Street Partners Investment Advisory LLC now owns 327 shares of the medical equipment provider’s stock worth $30,000 after purchasing an additional 149 shares during the last quarter. Root Financial Partners LLC purchased a new stake in Zimmer Biomet in the third quarter worth approximately $31,000. Finally, Mather Group LLC. bought a new stake in Zimmer Biomet in the 3rd quarter worth approximately $36,000. Institutional investors own 88.89% of the company’s stock.

Insider Buying and Selling at Zimmer Biomet

In related news, SVP Lori Winkler sold 2,650 shares of the company’s stock in a transaction on Thursday, March 12th. The shares were sold at an average price of $94.66, for a total transaction of $250,849.00. Following the completion of the transaction, the senior vice president owned 10,224 shares in the company, valued at approximately $967,803.84. This represents a 20.58% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.70% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on ZBH shares. Sanford C. Bernstein increased their price target on Zimmer Biomet from $97.00 to $99.00 and gave the company a “market perform” rating in a report on Friday, January 9th. Wall Street Zen cut Zimmer Biomet from a “buy” rating to a “hold” rating in a research report on Saturday, February 14th. Robert W. Baird reissued a “neutral” rating and issued a $100.00 target price (down from $117.00) on shares of Zimmer Biomet in a research report on Tuesday, December 16th. Citigroup reaffirmed a “buy” rating on shares of Zimmer Biomet in a research report on Wednesday, February 11th. Finally, The Goldman Sachs Group downgraded shares of Zimmer Biomet from a “neutral” rating to a “sell” rating and set a $93.00 price objective on the stock. in a report on Friday, January 9th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, ten have issued a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $106.20.

Zimmer Biomet Price Performance

Shares of Zimmer Biomet stock opened at $92.51 on Wednesday. The company has a market capitalization of $18.10 billion, a price-to-earnings ratio of 26.13, a PEG ratio of 1.90 and a beta of 0.58. The company has a quick ratio of 1.10, a current ratio of 1.98 and a debt-to-equity ratio of 0.55. The stock’s 50-day simple moving average is $92.37 and its 200-day simple moving average is $94.93. Zimmer Biomet Holdings, Inc. has a 52 week low of $84.59 and a 52 week high of $114.44.

Zimmer Biomet (NYSE:ZBH) last issued its earnings results on Tuesday, February 10th. The medical equipment provider reported $2.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.38 by $0.04. Zimmer Biomet had a return on equity of 12.93% and a net margin of 8.56%.The company had revenue of $2.24 billion for the quarter, compared to the consensus estimate of $2.22 billion. During the same quarter last year, the company earned $2.31 EPS. The firm’s quarterly revenue was up 10.9% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. As a group, analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, April 30th. Stockholders of record on Tuesday, March 31st will be issued a $0.24 dividend. This represents a $0.96 annualized dividend and a dividend yield of 1.0%. The ex-dividend date of this dividend is Tuesday, March 31st. Zimmer Biomet’s payout ratio is 27.12%.

Zimmer Biomet Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.